Filing Flows › Health Care › NutriBand (NTRB)
NutriBand (NTRB) earnings and revenue breakdown
Latest: Q2 FY27 · 10-Q filed Sep 4, 2026 · NutriBand (NTRB) Q2 FY27 earnings results →
Q2 FY27 Revenue down 30% year over year to $438K · 201¢ of every $1 of revenue lost · operating margin -203.6%
NutriBand made $438K in Q2 FY27 (-30% Y/Y). Operating margin -203.6%, net loss $881K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Sep 4, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $438K in Q2 FY27, down 30% year over year and up 1% from the previous quarter.
Operating costs exceeded revenue by $891K, an operating margin of -203.6%. The quarter ended with a net loss of $881K, narrower than the previous quarter's $1.2M loss.
Operating cash flow was −$585K. Non-cash charges added back $33K of depreciation and amortization. Working capital and other items added $262K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 FY27 | 10-Q | Sep 4, 2026 | $438K | -30% | -203.6% | −$881K | −$585K |
| Q1 FY27 | 10-Q | Jun 11, 2026 | $433K | -35% | -289.4% | −$1.2M | −$563K |
| Q4 FY26 | 10-K | Apr 29, 2026 | $401K | -38% | -254.8% | −$968K | −$732K |
| Q3 FY26 | 10-Q | Dec 11, 2025 | $346K | -46% | n/m | −$3.9M | −$1.8M |
| Q2 FY26 | 10-Q | Sep 9, 2025 | $622K | +41% | -321.8% | −$2.0M | −$1.3M |
| Q1 FY26 | 10-Q | May 30, 2025 | $667K | +63% | -211.8% | −$1.4M | −$1.3M |
| Q4 FY25 | 10-K | Apr 28, 2025 | $642K | +22% | -865.3% | −$5.5M | −$1.2M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About NutriBand
Nutriband Inc. (the “Company”, “Nutriband”, “we” or “us”), was incorporated in Nevada in January 2016. Our primary business is the development of a portfolio of transdermal pharmaceutical products. Our development pipeline primarily consists of transdermal products that are based on our proprietary AVERSA ™ abuse deterrent transdermal technology that we believe can be incorporated into existing transdermal patches that contain drugs that are susceptible to abuse and misuse such as opioid and stimulant drugs. The Company’s revenues are based on providing services through our subsidiaries Pocono Pharmaceuticals operating as Active Intelligence and 4P Therapeutics.
In its own words, from its 10-K, filed Apr 29, 2026.
NutriBand against its Orthopedic, Prosthetic & Surgical Appliances & Supplies peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -30% against the peers' median +9%. Operating margin: -203.6% against the peers' median 16.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| NTRB NutriBand | Q2 FY27 | $438K | -30% | -203.6% |
| ISRG Intuitive Surgical | Q3 2026 | $3.0B | +22% | 19.4% |
| ZBH Zimmer Biomet Holdings | Q3 2026 | $2.1B | +3% | 14.9% |
| EW Edwards Lifesciences | Q3 2026 | $1.7B | +10% | 17.4% |
| STE Steris | Q2 FY27 | $1.6B | +9% | 18.5% |
| ALGN Align Technology | Q3 2026 | $1.0B | +2% | 16.7% |
| ENOV Enovis | Q3 2026 | $559M | +2% | 0.6% |
| MSA MSA Safety | Q3 2026 | $536M | +14% | 16.4% |
| CDRE Cadre Holdings | Q3 2026 | $203M | +30% | 14.0% |
Source: NutriBand 10-Q on SEC EDGAR · CIK 1676047 · Orthopedic, Prosthetic & Surgical Appliances & Supplies
13F: who owns NTRB and who is buying
More on NTRB
History
Every quarter: Q2 FY27 results · Q1 FY27 results · Q4 FY26 results · Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results